已收盘 08-01 16:00:00 美东时间
-0.050
-3.47%
An announcement from Autonomix Medical, Inc. ( ($AMIX) ) is now available. On J...
07-23 05:30
Autonomix Medical (NASDAQ:AMIX) on Tuesday said it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up t...
07-22 20:54
Autonomix Medical, Inc. has entered into agreements with certain warrant holders to exercise or prepaid warrants for up to 1,477,596 shares at $1.723 per share, generating approximately $2.5 million in gross proceeds. New unregistered warrants will be issued, exercisable for the same number of shares at the same price, valid for five and a half years. The transaction is expected to close on July 23, 2025, with proceeds used for working capital an...
07-22 12:30
With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market
07-21 20:47
Drone stocks are taking off after hours Thursday after Defense Secretary Pete Hegseth issued new orders to fast-track drone manufacturing and deployment.
07-11 05:17
Autonomix Medical, Inc. (NASDAQ: AMIX) has published the latest CEO Corner segment on its website, where CEO Brad Hauser discusses the planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial. The company specializes in advancing precision nerve-targeted treatments, utilizing a first-in-class platform technology capable of detecting and differentiating neural signals with high sensitivity. Initially focused on treating...
07-07 12:30
Shares of Venus Concept Inc. (NASDAQ:VERO) rose sharply in today's pre-market t...
06-30 18:39
Autonomix Medical, Inc. has enrolled the first patient in its PoC 2 phase, expanding its technology beyond pancreatic cancer pain to address additional visceral cancers via the Celiac Plexus, doubling the addressable market. This phase builds on PoC 1's success, aiming to enhance clinical and commercial potential while targeting a broader range of pain conditions through innovative nerve ablation techniques.
06-30 12:30
Autonomix Medical Inc. announced the issuance of U.S. Patent No. 12,279,889 B2 by the USPTO, supporting its mission to advance minimally invasive nerve-focused treatments for high-need conditions. The patent covers systems and methods for locating, monitoring, and mapping electrophysiological signals during neuromodulation or denervation procedures, as well as tools to access small vessels for treatment of cancerous tumors and associated pain. Th...
06-27 12:00
Follow-on study ("PoC 2") builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technologyExpansion
06-05 20:49